MCID: PTH002
MIFTS: 49

Pathological Gambling

Categories: Mental diseases

Aliases & Classifications for Pathological Gambling

MalaCards integrated aliases for Pathological Gambling:

Name: Pathological Gambling 12 15 17 32
Compulsive Gambling 12 42
Gambling, Pathological 71
Gambling 43

Classifications:



External Ids:

Disease Ontology 12 DOID:12399
ICD9CM 34 312.31
MeSH 43 D005715
NCIt 49 C94335
SNOMED-CT 67 18085000
ICD10 32 F63.0
UMLS 71 C0030662

Summaries for Pathological Gambling

MedlinePlus : 42 Many people enjoy gambling, whether it's betting on a horse or playing poker on the Internet. Most people who gamble don't have a problem, but some lose control of their gambling. Signs of problem gambling include Always thinking about gambling Lying about gambling Spending work or family time gambling Feeling bad after you gamble, but not quitting Gambling with money you need for other things If you have concerns about your gambling, ask for help. Your health care provider can work with you to find the treatment that's best for you. NIH: National Institutes of Health

MalaCards based summary : Pathological Gambling, also known as compulsive gambling, is related to traumatic brain injury and stuttering. An important gene associated with Pathological Gambling is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Parkinson disease and Beta-Adrenergic Signaling. The drugs Methylphenidate and Ropinirole have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.

Related Diseases for Pathological Gambling

Diseases related to Pathological Gambling via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)
# Related Disease Score Top Affiliating Genes
1 traumatic brain injury 30.4 DRD2 COMT
2 stuttering 30.3 SLC6A3 DRD2 DBH
3 body dysmorphic disorder 30.2 SLC6A4 MAOA HTR2A
4 trichotillomania 30.2 DRD4 DRD3 DRD2
5 somatization disorder 30.1 SLC6A4 HTR2A
6 frontotemporal dementia 30.0 SLC6A4 MAOA DRD4 DNAJB6
7 drug dependence 30.0 SLC6A4 SLC6A3 DRD3 DRD2 DRD1 ANKK1
8 opioid addiction 30.0 DRD2 COMT
9 avoidant personality disorder 29.9 WASF1 TPH1 SLC6A4 SLC6A3 MAOA DRD4
10 dependent personality disorder 29.9 WASF1 DRD4
11 schizoid personality disorder 29.8 WASF1 DRD2
12 hyperprolactinemia 29.8 HTR2A DRD4 DRD2 DBH
13 adjustment disorder 29.6 SLC6A4 HTR2A HTR1A
14 cyclothymic disorder 29.6 HTR2A DRD4 DRD2 COMT
15 movement disease 29.5 SLC6A3 MAOB DRD5 DRD4 DRD3 DRD2
16 withdrawal disorder 29.5 HTR1A DRD2 DRD1
17 amnestic disorder 29.5 HTR1A DRD2 DRD1
18 depression 29.4 TPH1 SLC6A4 MAOA HTR2A HTR1A
19 cannabis dependence 29.4 WASF1 DRD2 COMT
20 neurotic disorder 29.3 SLC6A4 MAOA HTR2A HTR1A
21 eating disorder 29.3 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 COMT
22 bulimia nervosa 29.3 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
23 cannabis abuse 29.2 WASF1 DRD4 DRD2 COMT
24 cocaine abuse 29.2 SLC6A4 SLC6A3 MAOB DRD3 DRD2 DRD1
25 alexithymia 29.1 SLC6A4 HTR1A DRD2 COMT ANKK1
26 sexual disorder 29.1 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
27 fibromyalgia 29.0 SLC6A4 HTR2A HTR1A DRD2 COMT
28 separation anxiety disorder 29.0 WASF1 SLC6A4 SLC6A3 RTN4 DRD4
29 opiate dependence 29.0 TPH1 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
30 cocaine dependence 29.0 SLC6A4 SLC6A3 MAOB HTR2A DRD3 DRD2
31 dysthymic disorder 29.0 WASF1 SLC6A4 MAOA HTR2A HTR1A
32 sleep disorder 28.9 SLC6A4 SLC6A3 HTR2A HTR1A DRD2
33 pyromania 28.9 WASF1 RTN4 MAOA DRD2 DNER
34 obsessive-compulsive personality disorder 28.9 WASF1 SLC6A4 HTR2A DRD3 COMT
35 dementia 28.8 SLC6A3 MAOB HTR2A HTR1A DRD2 COMT
36 restless legs syndrome 28.7 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4
37 heroin dependence 28.5 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DRD1
38 schizoaffective disorder 28.4 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
39 irritable bowel syndrome 28.4 TPH1 SLC6A4 HTR2A HTR1A COMT
40 conduct disorder 28.4 TPH1 SLC6A4 SLC6A3 MAOA DRD5 DRD4
41 intermittent explosive disorder 28.4 SLC6A4 MAOA HTR2A HTR1A DRD2 COMT
42 anorexia nervosa 28.4 TPH1 SLC6A4 MAOA HTR2A HTR1A DRD4
43 borderline personality disorder 28.3 TPH1 SLC6A4 SLC6A3 MAOA HTR2A HTR1A
44 delusional disorder 28.3 SLC6A3 HTR2A HTR1A DRD5 DRD4 DRD3
45 bipolar i disorder 28.2 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
46 post-traumatic stress disorder 28.2 SLC6A4 MAOB MAOA HTR2A HTR1A DRD2
47 generalized anxiety disorder 28.2 TPH1 SLC6A4 SLC6A3 MAOA HTR2A HTR1A
48 agoraphobia 28.1 WASF1 SLC6A4 MAOA HTR2A HTR1A COMT
49 social phobia 28.0 WASF1 SLC6A4 MAOA HTR1A DRD2 COMT
50 autism spectrum disorder 28.0 SLC6A4 SLC6A3 MAOB MAOA HTR2A DRD5

Graphical network of the top 20 diseases related to Pathological Gambling:



Diseases related to Pathological Gambling

Symptoms & Phenotypes for Pathological Gambling

GenomeRNAi Phenotypes related to Pathological Gambling according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.28 ANKK1 COMT DNAJB6 DRD1 DRD2 DRD4

MGI Mouse Phenotypes related to Pathological Gambling:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 COMT DBH DNER DRD1 DRD2 DRD3
2 cardiovascular system MP:0005385 10 COMT DBH DRD1 DRD2 DRD3 DRD5
3 homeostasis/metabolism MP:0005376 9.93 COMT DBH DRD1 DRD2 DRD3 DRD4
4 muscle MP:0005369 9.5 DRD1 DRD2 HTR2A SLC6A3 SLC6A4 TPH1
5 nervous system MP:0003631 9.5 COMT DBH DNER DRD1 DRD2 DRD3

Drugs & Therapeutics for Pathological Gambling

Drugs for Pathological Gambling (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
2
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
3
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
4
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
5
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
8 Central Nervous System Stimulants Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Cytochrome P-450 Enzyme Inhibitors Phase 4
12
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
13
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
14
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
15
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
16
Ethanol Approved Phase 3 64-17-5 702
17 Excitatory Amino Acid Antagonists Phase 2, Phase 3
18 Anesthetics Phase 2, Phase 3
19 Anesthetics, Dissociative Phase 2, Phase 3
20 Anesthetics, General Phase 2, Phase 3
21 Anesthetics, Intravenous Phase 2, Phase 3
22 Gastrointestinal Agents Phase 3
23 Antiemetics Phase 3
24 Dopamine Agents Phase 3
25 Dopamine Antagonists Phase 3
26 Psychotropic Drugs Phase 3
27 Antipsychotic Agents Phase 3
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Memantine Approved, Investigational Phase 2 19982-08-2 4054
30
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
31
Fluphenazine Approved Phase 2 69-23-8 3372
32
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
33
Haloperidol Approved Phase 2 52-86-8 3559
34
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
35
Milk thistle Approved, Experimental, Investigational Phase 2 65666-07-1
36
Pimavanserin Approved, Investigational Phase 2 706779-91-1 16058810
37
Naloxone Approved, Vet_approved Phase 2 465-65-6 5284596
38
Sertraline Approved Phase 2 79617-96-2 68617
39
Rimonabant Approved, Investigational Phase 2 158681-13-1, 168273-06-1 104850
40
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862
41 Ecopipam Investigational Phase 2 112108-01-7
42 Catechol Phase 2
43 Adrenergic Agents Phase 2
44 Fluphenazine enanthate Phase 2
45 Fluphenazine depot Phase 2
46 Haloperidol decanoate Phase 2
47 Sympathomimetics Phase 2
48 Respiratory System Agents Phase 2
49 Anti-Infective Agents Phase 2
50 Antidotes Phase 2

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
2 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
3 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
4 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
5 Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
6 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles. Completed NCT01733199 Phase 4
7 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
8 Neuropsychological and Psychopathological Prognosis Factors of Smoking Cessation Completed NCT01554436 Phase 4
9 Neurocognitive and Metabolic Effects of Mild Hypothyroidism Completed NCT00565864 Phase 4 L-thyroxine (L-T4)
10 An Open Prospective Trial of IV Ketamine in Suicidal Adolescents Unknown status NCT02048423 Phase 2, Phase 3 Ketamine
11 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
12 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
13 Minimal and Brief Treatments for Pathological Gamblers: Developing Effective Treatment Systems Completed NCT00203645 Phase 3
14 Naltrexone Treatment in Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
15 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
16 The Efficacy of Functional Magnetic Resonance Imaging (fMRI) Guided Low Frequency Repetitive Magnetic Transcranial Stimulation (rTMS) Therapy on Symptoms of Generalized Anxiety Disorder (GAD) Completed NCT00662584 Phase 3
17 Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation Recruiting NCT03669315 Phase 3
18 Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects Recruiting NCT03227562 Phase 3 RisperiDONE 0.5 MG
19 EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents Active, not recruiting NCT02016378 Phase 3
20 Topiramate in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study Terminated NCT00245583 Phase 3 Topiramate;Placebo
21 RTC of Web Versus In-Person SUD and Comorbidity Treatment Unknown status NCT01529047 Phase 2
22 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene
23 A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling Completed NCT00585169 Phase 2 Memantine Hydrochloride
24 Ecopipam Treatment of Pathological Gambling Completed NCT01215357 Phase 2 Ecopipam
25 Tolcapone Treatment of Pathological Gambling: An Open-Label Study Completed NCT00927563 Phase 2 Tolcapone
26 Indicated Prevention With At-Risk Gamblers Completed NCT00078273 Phase 2
27 Double-blind Placebo Controlled Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
28 Cognitive Behavioral Therapy for Pathological Gambling Completed NCT00337753 Phase 2
29 Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
30 Double Blind Controlled Trial of Topiramate for Compulsive Buying Completed NCT02138058 Phase 2 Topiramate
31 Double-Blind Placebo-Controlled Investigation of Naltrexone for Pathological Gambling Completed NCT01057862 Phase 2 Naltrexone
32 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Completed NCT00967005 Phase 2 N Acetyl Cysteine
33 Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
34 Use of Massage Therapy to Reduce Anxiety and Improve Sleep in Patients Participating in an Inpatient Withdrawal Management (Detox) Program: A Randomized Controlled Pilot Study Completed NCT00992979 Phase 2
35 Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study Recruiting NCT02337634 Phase 2 Placebo;Milk Thistle
36 Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease Recruiting NCT03947216 Phase 2 Active drug: pimavanserin 17mg (2 strength tablets);Placebo: 2 tablets containing same excipients except active compound
37 Double-blind, Placebo-controlled Randomised Study on the Efficacy of Naloxone Nasal Spray for the Treatment of Gambling Disorder Enrolling by invitation NCT03430180 Phase 2 Naloxone hydrochloride;Placebo
38 Biological Signature and Safety of an Immunomodulatory Probiotic Intervention for Veterans With PTSD Not yet recruiting NCT04150380 Phase 2
39 A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence Terminated NCT00249431 Phase 2 Sertraline
40 Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers Terminated NCT01764685 Phase 2 Topiramate;Placebo
41 The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia Terminated NCT00547118 Phase 2 Rimonabant;Placebo
42 Clinical Assessment of Topiramate on Gambling-Related Behaviours in Problem Gamblers: Effects of Gender and Negative Emotionality Withdrawn NCT00370188 Phase 2 Topiramate
43 Evaluating the Benefits of the Community Reinforcement and Family Training(CRAFT) Approach to Concerned Significant Others(CSO) of Individuals Engaged in Problem Gambling (IPGs) Withdrawn NCT01340274 Phase 2
44 Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Unknown status NCT01154712 Phase 1
45 Enhanced Cognitive Behavior Therapy for the Treatment of Pathological Gambling Completed NCT00118391 Phase 1
46 Cognitive Behavioral Treatment for Pathological Gambling Completed NCT00158314 Phase 1
47 Cognitive-Motivational Behavior Therapy for Gamblers Completed NCT00069420 Phase 1
48 An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling Completed NCT00273702 Phase 1 N-Acetyl Cysteine
49 Acute Effects of Smoked Marijuana on Decision Making, as Assessed by a Modified Gambling Task, in Experienced Marijuana Users Completed NCT00373399 Phase 1 Inactive Marijuana (0% THC);Low THC marijuana (1.8 %THC);High THC marijuana (3.9% THC)
50 Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) Completed NCT01437293 Phase 1 L-dopa / carbidopa / entacapone (LCE)

Search NIH Clinical Center for Pathological Gambling

Cochrane evidence based reviews: gambling

Genetic Tests for Pathological Gambling

Anatomical Context for Pathological Gambling

MalaCards organs/tissues related to Pathological Gambling:

40
Brain, Cortex, Testes, Prefrontal Cortex, Subthalamic Nucleus, Eye, Liver

Publications for Pathological Gambling

Articles related to Pathological Gambling:

(show top 50) (show all 1901)
# Title Authors PMID Year
1
Commentary on Nilsson et al. (2020): The development of effective interventions for concerned significant others affected by gambling harms. 42
32196805 2020
2
Early intervention and identification of gambling disorder: a systematic literature review of strategies implemented by gambling operators. 42
32228812 2020
3
Manaaki - a cognitive behavioral therapy mobile health app to support people experiencing gambling problems: a randomized control trial protocol. 42
32028926 2020
4
The influence of chronological age on cognitive biases and impulsivity levels in male patients with gambling disorder. 61
32573467 2020
5
Gender Differences in Gambling Exposure and At-risk Gambling Behavior. 61
31471835 2020
6
Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model. 61
31423741 2020
7
[The gambling industry: a public health perspective.] 61
32536686 2020
8
Striatal dynamics as determinants of reduced gambling vulnerability in the NHE rat model of ADHD. 61
32045636 2020
9
Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. 61
32450545 2020
10
Gambling formats, involvement, and problem gambling: which types of gambling are more risky? 61
32423451 2020
11
Gambling in nursing students of the University of Palermo. 61
32266367 2020
12
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. 61
32246399 2020
13
Shared gray matter alterations in individuals with diverse behavioral addictions: A voxel-wise meta-analysis. 61
32359230 2020
14
Pre-clinical models of reward deficiency syndrome: A behavioral octopus. 61
32360413 2020
15
Unpacking common and distinct neuroanatomical alterations in cocaine dependent versus pathological gambling. 61
32088112 2020
16
The neurochemical substrates of habitual and goal-directed control. 61
32127520 2020
17
Basolateral amygdala - nucleus accumbens circuitry regulates optimal cue-guided risk/reward decision making. 61
31811876 2020
18
Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. 61
30671764 2020
19
Mind the GAP! Pathological gambling, a modern defy to public health. 61
31944213 2020
20
Impaired Awareness of Problem and Pathological Gambling: A Review. 61
31863419 2020
21
[Feasibility study of therapeutic exposure in virtual reality for pathological gamblers]. 61
31761313 2020
22
Orbitofrontal Sulcogyral Pattern as a Transdiagnostic Trait Marker of Early Neurodevelopment in the Social Brain. 61
32028799 2020
23
Cannabis use, problem-gambling severity, and psychiatric disorders: Data from the National Epidemiological Survey on Alcohol and Related Conditions. 61
31246071 2020
24
Presence of problematic and disordered gambling in older age and validation of the South Oaks Gambling Scale. 61
32428026 2020
25
Deficient Decision Making in Pathological Gamblers Correlates With Gray Matter Volume in Medial Orbitofrontal Cortex. 61
32194455 2020
26
Exploring Pathways to Gambling: Proposing the Integrated Risk and Protective Factors Model of Gambling Types. 61
31965384 2020
27
Different aspects of impulsivity in chronic alcohol use disorder with and without comorbid problem gambling. 61
31999707 2020
28
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. 61
32432025 2020
29
A systematic review of gambling-related findings from the National Epidemiologic Survey on Alcohol and Related Conditions. 61
31830810 2019
30
Factors Precipitating Calls to a Help Hotline: A Comparison of Whites, Blacks, and Hispanics. 61
30604034 2019
31
The Multidimensional Structure of Problem Gambling: An Evaluation of Four Gambling Categorization Instruments from an International Online Survey of Gamblers. 61
30793249 2019
32
[Gambling and Gaming disorders and physical health of players: A critical review of the literature]. 61
31767247 2019
33
What's in a Name? Evaluating the Public Stigma of Gambling Disorder. 61
31848837 2019
34
Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study. 61
31688453 2019
35
Adult ADHD Is Associated With Gambling Severity and Psychiatric Comorbidity Among Treatment-Seeking Problem Gamblers. 61
28162086 2019
36
Mobile Phone Addiction Among Children and Adolescents: A Systematic Review. 61
31800517 2019
37
The Risk of Gambling Problems in the General Population: A Reconsideration. 61
31628592 2019
38
[Gambling disorder and imputability: from the nosographic revision to an expanded forensic assessment]. 61
31657803 2019
39
Cognitive Distortions of Patients in the Gambling Addicts' Club - Differences with Regard to Age and Length of Treatment. 61
31596824 2019
40
Striatal presynaptic dopaminergic dysfunction in gambling disorder: A 123 I-FP-CIT SPECT study. 61
30226290 2019
41
Religiosity and Chance Beliefs in Persons with DSM-IV Pathological Gambling Enrolled in a Longitudinal Follow-Up Study. 61
31115747 2019
42
An Exploratory Study of Relationships Among Five-Factor Personality Measures and Forms of Gambling in Adults With and Without Probable Pathological Gambling. 61
30382456 2019
43
Overlapping dimensional phenotypes of impulsivity and compulsivity explain co-occurrence of addictive and related behaviors. 61
30458896 2019
44
Effects of nicotine exposure and anxiety on motivation for reward and gambling-like cues under reward uncertainty. 61
30869950 2019
45
Addiction beyond pharmacological effects: The role of environment complexity and bounded rationality. 61
31125913 2019
46
Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decision-making. 61
29888425 2019
47
Expectation of reward differentially modulates executive inhibition. 61
31443739 2019
48
Let's Call it Quits: Break-Even Effects in the Decision to Stop Taking Risks. 61
30650213 2019
49
Prevalence of Gambling Disorder Among Prisoners: A Systematic Review. 61
31315486 2019
50
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. 61
30848825 2019

Variations for Pathological Gambling

Expression for Pathological Gambling

Search GEO for disease gene expression data for Pathological Gambling.

Pathways for Pathological Gambling

Pathways related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.03 SLC6A3 RTN4 MAOB MAOA DRD2 DRD1
2
Show member pathways
12.67 DRD5 DRD4 DRD3 DRD2 DRD1
3 12.49 TPH1 RTN4 HTR1A DBH COMT
4
Show member pathways
12.48 SLC6A3 MAOB MAOA DRD5 DRD4 DRD3
5 12.3 DRD5 DRD4 DRD3 DRD2 DRD1
7 12.2 HTR1A DRD5 DRD2 DRD1
8 12.1 TPH1 SLC6A4 MAOA HTR2A HTR1A
9
Show member pathways
11.93 SLC6A3 MAOB MAOA DRD2 DRD1
10 11.86 TPH1 SLC6A4 MAOB MAOA HTR2A HTR1A
11
Show member pathways
11.85 DRD4 DRD2 DRD1
12 11.81 HTR2A DRD4 DRD3
13
Show member pathways
11.8 DRD4 DRD3 DRD2
14
Show member pathways
11.75 TPH1 MAOB MAOA
15 11.74 TPH1 MAOA DBH
16 11.72 HTR2A DRD2 DRD1
17
Show member pathways
11.72 MAOB MAOA DBH COMT
18
Show member pathways
11.69 TPH1 MAOB MAOA
19
Show member pathways
11.54 HTR2A HTR1A DRD5 DRD4 DRD3 DRD2
20
Show member pathways
11.41 SLC6A4 SLC6A3 MAOA DBH
21
Show member pathways
11.1 SLC6A4 SLC6A3 MAOA COMT
22 11.1 TPH1 SLC6A4 MAOA HTR2A HTR1A
23
Show member pathways
11.01 TPH1 MAOA DBH COMT
24 10.94 DRD2 ANKK1
25
Show member pathways
10.9 MAOB MAOA COMT
26 10.83 MAOB MAOA COMT
27
Show member pathways
10.76 SLC6A4 SLC6A3 MAOB MAOA HTR1A DRD5
28
Show member pathways
10.73 MAOB MAOA

GO Terms for Pathological Gambling

Cellular components related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.36 SLC6A4 SLC6A3 RTN4 MAOB MAOA HTR2A
2 plasma membrane GO:0005886 10.31 SLC6A4 SLC6A3 RTN4 HTR2A HTR1A DRD5
3 integral component of membrane GO:0016021 10.24 SLC6A4 SLC6A3 RTN4 MAOB MAOA HTR2A
4 integral component of plasma membrane GO:0005887 10.06 SLC6A4 SLC6A3 HTR2A HTR1A DRD5 DRD4
5 cell GO:0005623 10.04 RTN4 HTR2A DRD5 DRD4 DRD3 DRD2
6 glutamatergic synapse GO:0098978 9.88 HTR2A DRD4 DRD3 DRD2 DRD1
7 synapse GO:0045202 9.81 WASF1 SLC6A4 HTR2A HTR1A DRD5 DRD3
8 dendrite GO:0030425 9.8 HTR2A HTR1A DRD4 DRD2 DRD1 DNER
9 GABA-ergic synapse GO:0098982 9.7 DRD3 DRD2 DRD1
10 ciliary membrane GO:0060170 9.69 DRD5 DRD2 DRD1
11 non-motile cilium GO:0097730 9.61 DRD5 DRD2 DRD1
12 9+0 non-motile cilium GO:0097731 9.55 DRD5 DRD1
13 dopaminergic synapse GO:0098691 9.5 SLC6A3 DRD3 DRD2
14 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR2A DRD2 DRD1
15 integral component of postsynaptic membrane GO:0099055 9.02 SLC6A4 SLC6A3 HTR2A DRD2 DRD1

Biological processes related to Pathological Gambling according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.25 HTR2A HTR1A DRD5 DRD4 DRD3 DRD2
2 chemical synaptic transmission GO:0007268 10.05 HTR2A HTR1A DRD5 DRD4 DBH
3 cell-cell signaling GO:0007267 10.03 DRD5 DRD3 DRD2 DRD1
4 response to drug GO:0042493 10.01 SLC6A4 SLC6A3 MAOB HTR2A DRD3 DRD2
5 response to ethanol GO:0045471 9.96 SLC6A3 MAOB DRD3 DRD2
6 cellular calcium ion homeostasis GO:0006874 9.96 HTR2A DRD5 DRD4 DRD3
7 locomotory behavior GO:0007626 9.96 SLC6A3 DRD3 DRD2 DRD1 DBH
8 response to toxic substance GO:0009636 9.94 SLC6A4 MAOB DRD3 DRD2
9 memory GO:0007613 9.93 SLC6A4 HTR2A DRD1 DBH
10 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.92 DRD5 DRD3 DRD2 DRD1
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.91 HTR2A HTR1A DRD4 DRD1
12 learning GO:0007612 9.89 DRD3 DRD1 COMT
13 synapse assembly GO:0007416 9.89 DRD2 DRD1 DNER
14 regulation of synaptic vesicle exocytosis GO:2000300 9.88 HTR2A DRD2 DRD1
15 visual learning GO:0008542 9.88 DRD3 DRD2 DRD1 DBH
16 social behavior GO:0035176 9.87 SLC6A4 DRD4 DRD3
17 associative learning GO:0008306 9.87 DRD5 DRD2 DRD1 DBH
18 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.86 DRD3 DRD2 DRD1
19 regulation of dopamine secretion GO:0014059 9.85 HTR2A DRD3 DRD2
20 behavioral fear response GO:0001662 9.85 HTR1A DRD4 DRD1
21 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.85 HTR2A HTR1A DRD4
22 response to cocaine GO:0042220 9.85 SLC6A3 DRD5 DRD3 DRD2 DRD1
23 negative regulation of blood pressure GO:0045776 9.84 DRD5 DRD3 DRD2
24 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.84 DRD5 DRD3 DRD2 DRD1
25 negative regulation of protein secretion GO:0050709 9.82 DRD4 DRD3 DRD2
26 arachidonic acid secretion GO:0050482 9.82 DRD4 DRD3 DRD2
27 temperature homeostasis GO:0001659 9.81 HTR2A DRD2 DRD1
28 prepulse inhibition GO:0060134 9.81 SLC6A3 DRD3 DRD2 DRD1
29 behavioral response to ethanol GO:0048149 9.8 DRD4 DRD3 DRD2 DBH
30 negative regulation of voltage-gated calcium channel activity GO:1901386 9.79 DRD4 DRD3 DRD2
31 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.79 HTR2A DRD3 DRD2
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.78 DRD5 DRD3 DRD2 DRD1
33 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.77 DRD5 DRD3 DRD1
34 neurotransmitter catabolic process GO:0042135 9.77 MAOB MAOA COMT
35 dopamine receptor signaling pathway GO:0007212 9.77 DRD5 DRD4 DRD3 DRD2 DRD1
36 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.76 DRD4 DRD3 DRD2
37 response to pain GO:0048265 9.75 DBH COMT
38 transmission of nerve impulse GO:0019226 9.75 DRD5 DRD1
39 response to iron ion GO:0010039 9.75 SLC6A3 DRD2
40 negative regulation of cytosolic calcium ion concentration GO:0051481 9.75 DRD3 DRD2
41 long-term synaptic depression GO:0060292 9.75 DRD5 DRD1
42 vasoconstriction GO:0042310 9.74 SLC6A4 HTR1A
43 behavior GO:0007610 9.74 HTR2A HTR1A
44 neurotransmitter biosynthetic process GO:0042136 9.74 SLC6A4 SLC6A3
45 positive regulation of renal sodium excretion GO:0035815 9.74 DRD3 DRD2
46 grooming behavior GO:0007625 9.74 DRD2 DRD1
47 G protein-coupled receptor internalization GO:0002031 9.74 DRD3 DRD2
48 maternal behavior GO:0042711 9.74 DRD1 DBH
49 striatum development GO:0021756 9.73 DRD2 DRD1
50 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.73 DRD4 DRD3

Molecular functions related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.98 HTR2A HTR1A DRD5 DRD4 DRD3 DRD2
2 neurotransmitter receptor activity GO:0030594 9.69 HTR2A HTR1A DRD4
3 drug binding GO:0008144 9.65 SLC6A3 HTR2A DRD4 DRD3 DRD2
4 G protein-coupled serotonin receptor activity GO:0004993 9.63 HTR2A HTR1A DRD4
5 serotonin binding GO:0051378 9.54 SLC6A4 HTR2A HTR1A
6 neurotransmitter:sodium symporter activity GO:0005328 9.52 SLC6A4 SLC6A3
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.5 DRD4 DRD3 DRD2
8 monoamine transmembrane transporter activity GO:0008504 9.49 SLC6A4 SLC6A3
9 primary amine oxidase activity GO:0008131 9.48 MAOB MAOA
10 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
11 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.4 DRD5 DRD1
12 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
13 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Pathological Gambling

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....